Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408303 · ClinicalTrials.gov registry record · Phase 3
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
A Phase 3 study of Cardiovascular Disease and Hypertriglyceridemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 646
- Enrollment target
- 20
- Study locations
NCT01408303 is a Phase 3 study of Cardiovascular Disease and Hypertriglyceridemia that has completed, run by AstraZeneca. The registered enrollment target is 646 participants, below the 2,709-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT01408303, a Phase 3 study of Cardiovascular Disease and Hypertriglyceridemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 646 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to evaluate the efficacy of adding Epanova (2 g or 4 g daily) to an optimal statin monotherapy for lowering non-high-density lipoprotein (non-HDL) cholesterol in subjects with persistent hypertriglyceridemia and high risk for cardiovascular disease.
Conditions Studied
Interventions
- DRUG Olive oil, 4g
- DRUG omega-3-carboxylic acids, 2g
- DRUG omega-3-carboxylic acids, 4g
Study Locations (20)
California
- - Encinitas
- - Lomita
- - Los Angeles
- - Sacramento
- - San Diego
- - Spring Valley
- - Westlake Village
Florida
- - Brandon
- - Clearwater
- - Coral Gables
- - Hialeah
- - Jacksonville
- - Jacksonville
- - Jupiter
Arizona
- - Chandler
- - Phoenix
Colorado
- - Colorado Springs
- - Denver
Alabama
- - Muscle Shoals
Arkansas
- - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408303
The ClinicalTrials.gov registry entry for NCT01408303 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,709-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (76% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 3 interventions - of which Olive oil, 4g is the first listed.
NCT01408303 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01408303 about?
NCT01408303 is a clinical study titled "[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL". The primary objective is to evaluate the efficacy of adding Epanova (2 g or 4 g daily) to an optimal statin monotherapy for lowering non-high-density lipoprotein (non-HDL) cholesterol in subjects with persistent hypertriglyceridemia and high risk for cardiovascular disease.
What is the current status of trial NCT01408303?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 646 participants. The study started on 2011-08. Estimated completion is 2012-06.
What conditions does trial NCT01408303 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Hypertriglyceridemia.
What interventions are being tested in trial NCT01408303?
The interventions under investigation include: Olive oil, 4g (DRUG), omega-3-carboxylic acids, 2g (DRUG), omega-3-carboxylic acids, 4g (DRUG).
Who is sponsoring clinical trial NCT01408303?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01408303 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RECRUITING · Phase 3
-
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RECRUITING · Phase 3
-
VITAL Rhythm Study
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
ACTIVE NOT RECRUITING · Phase 3
-
Vitamin D and Omega-3 Trial (VITAL)
ACTIVE NOT RECRUITING · Phase 3
-
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.